- Condition: Prostate Cancer
Intervention: Radiation: focal salvage HDR prostate brachytherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Not yet recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Other: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified May 2012 - Condition: Benign Prostate Hyperplasia
Interventions: Procedure: HOLEP (Holmium Laser Enucleation of The Prostate); Procedure: PVP-XPS (Photoselective Vaporization of the Prostate)
Sponsors: Royal Victoria Hospital, Canada; Royal Victoria Hospital, Canada; McGill University
Recruiting - verified January 2012 - Condition: High-risk Prostate Cancer
Interventions: Radiation: Standard Radiation Treatment; Radiation: Hypofractionated radiation treatment
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Colorectal Cancer; Colorectal Polyps
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011 - Condition: Prostate Cancer Recurrent
Intervention: Drug: degarelix
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; Ferring Inc.
Not yet recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Degarelix
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Not yet recruiting - verified November 2011 - Condition: Prostate Cancer
Interventions: Radiation: hypofractionation; Radiation: conventional
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital
Not yet recruiting - verified September 2011 - Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiation
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified January 2012 - FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate CancerCondition: Prostate Cancer
Interventions: Radiation: Stereotactic Body Radiation; Drug: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified September 2011 - Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Conditions: Prostate Neoplasms; Prostate Cancer
Interventions: Drug: Abiraterone acetate and prednisone; low-fat diet; Drug: Abiraterone acetate and prednisone; high-fat diet
Sponsors: Janssen-Ortho Inc., Canada; Janssen-Ortho Inc., Canada
Recruiting - verified May 2012 - Condition: Prostatic Neoplasms
Interventions: Radiation: Image-guided radiotherapy; Radiation: Image-guided radiotherapy
Sponsors: CancerCare Manitoba; CancerCare Manitoba; Sunnybrook Health Sciences Centre
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Abbott; Abbott; JSS Medical Research Inc.; CMX Research; CMX Research Inc
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: CMX Research; CMX Research; Ferring Pharmaceuticals
Recruiting - verified February 2012 - Condition: Urinary Incontinence
Interventions: Drug: solifenacin succinate; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012 - Condition: Prostate Cancer
Intervention: Device: MRI assisted TRUS guided biopsy
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; OICR; Eigen
Recruiting - verified March 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services; Canadian Association of Radiation Oncology; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: PX-866
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Oncothyreon Canada Inc.
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Overactive Bladder
Interventions: Drug: Fesoterodine 8mg; Drug: Fesoterodine 4mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Overactive Bladder; Bladder, Overactive; Overactive Urinary Bladder
Interventions: Drug: Fesoterodine 8 mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: cediranib maleate; Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Prostate Cancer Metastatic
Intervention: Drug: CABAZITAXEL
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012 - Conditions: Prostate Cancer; Interstitial Radiation; High Dose Rate Brachytherapy; Ultrasound-based Planning Compared to CT-based Planning
Intervention: Radiation: HDR prostate brachytherapy
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Recruiting - verified June 2011 - Condition: Localized Low-Risk Prostate Cancer
Intervention: Device: MRgFUS Treatment
Sponsors: InSightec; InSightec
Recruiting - verified February 2012 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Other: MRI examination
Sponsors: Radboud University; Radboud University; Siemens AG; Mount Vernon Hospital; Multi-Imagem and CDPI, Rio de Janeiro, Brasil; Norwegian University of Science and Technology; University of California, Los Angeles; University Hospital, Ghent; Johns Hopkins University; German Cancer Research Center; Medical University of Vienna; University Health Network, Toronto; University of Heidelberg
Recruiting - verified July 2011 - Condition: Castration Resistant Prostate Cancer
Interventions: Drug: OGX-427 and Prednisone; Drug: Prednisone
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; OncoGenex Technologies, Inc.
Recruiting - verified December 2011 - Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Bladder Cancer
Intervention: Drug: OGX-427
Sponsors: Vancouver Coastal Health; Vancouver Coastal Health; NCIC Clinical Trials Group; Vancouver General Hospital Foundation
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Prostate Cancer; Erectile Dysfunction; Urinary Toxicity
Interventions: Drug: LHRH agonist and Bicalutamide; Drug: Bicalutamide, Dutasteride and Tamoxifen
Sponsors: Centre hospitalier universitaire de Québec; Centre hospitalier universitaire de Québec; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1Condition: Prostate Cancer
Intervention: Biological: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
Sponsors: McMaster University; Hamilton Health Sciences Corporation
Recruiting - verified December 2011 - Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate CancerConditions: Cancer of the Prostate; Prostate Cancer; Prostatic Neoplasms
Interventions: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E; Drug: Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011 - Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: USHIFU, LLC; USHIFU, LLC
Recruiting - verified April 2012 - Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism
Interventions: Device: Comprehensive computed tomography of the abdomen/pelvis; Other: Limited Malignancy Screening
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011 - Condition: Prostate Cancer
Intervention: Procedure: 3T MR Spectroscopy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified June 2011 - Condition: Prostate Cancer
Interventions: Procedure: 3T MR Imaging; Procedure: C-Choline PET Scanning; Procedure: Gene Rearrangement
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Conditions: Bone Metastases; Multiple Myeloma
Interventions: Device: ExAblate 2000; Device: Sham
Sponsors: InSightec; InSightec
Recruiting - verified October 2011 - Conditions: Hematuria; Hematospermia
Intervention: Drug: Finasteride
Sponsors: University of British Columbia; University of British Columbia; Health Canada; Merck Frosst Canada Ltd.
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012 - Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011 - Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011 - Condition: Prostate Cancer
Intervention: Drug: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Procedure: Androgen suppression, radiotherapy; Procedure: Androgen suppression, radiotherapy, iodine 125 brachytherapy
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Biological: OGX-011
Sponsors: University of British Columbia; University of British Columbia; Department of Defense
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified April 2009
 |
Join Clinical Trials in Fort Smith, Arkansas |
